查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363191

卵巢癌治療的市場規模、佔有率和趨勢分析報告：按治療層級、治療、最終用途、地區和細分市場預測，2023-2030

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 94 Pages | 商品交期: 2-10個工作天內

價格

卵巢癌藥物市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，預計2030年全球卵巢癌藥物市場規模將達到56.5億美元，2023年至2030年年複合成長率為6.6%。

該市場的成長主要是由新藥採用的增加和強大的管道的存在等要素所推動的。由於老年人口增加和不健康的生活方式，卵巢癌罹患率上升正在推動市場發展。

卵巢癌佔女性所有惡性的3.0%，佔女性癌症死亡人數的6.0%。 2016 年，卵巢癌在全球造成 235,200新患者和 140,000 例死亡，其中北美和歐洲的發生率最高。

二線和三線非鉑類PARP和VEGF抑制劑的引入極大地改變了卵巢癌的治療策略。據估計，幾種生物製藥和小分子療法，包括正在開發的抗體藥物複合體(ADC)，將對卵巢癌的治療譜產生重大影響。

卵巢癌治療藥物市場報告亮點

  • 以治療方法計算，醫院藥局板塊2022年銷售佔有率最大，為45.37%。政府對癌症研究和治療的配合措施和資助的增加促進了藥物的開發和可近性，醫院現在可以提供有效的卵巢癌治療。按用途，商業細分市場佔據最大銷售佔有率，2022 年將達到 88.0%。這是由於對學名藥的需求增加，而慢性病的高負擔也促進了成長。
  • 例如，據澳洲聯邦稱，2020 年，澳洲政府撥款 1,620 萬美元用於八個專注於對抗卵巢癌的研究計畫。在澳洲和全球整體內，卵巢癌一直是所有女性癌症中存活率最低的。平均而言，每 100 名被診斷出患有卵巢癌的女性中，有 43 人在診斷後 5 年內仍存活。
  • 線上藥局部門預計在預測期內將以 8.1% 的最快年複合成長率成長。便利性，特別是對於健康狀況不佳的患者而言，正在推動卵巢癌藥物市場中線上藥房的發展，因為線上藥房方便訂購卵巢癌藥物並將其直接運送到患者家中，這是促進因素。這種可近性消除了獲取基本藥物的障礙，提高了患者對治療方法的依從性，並擴大了這些藥物的市場範圍。
  • 例如，AdooQ BioScience 為客戶提供了一個方便的平台來訂購卵巢癌藥物，特別是 rucaparib。在該網頁上，客戶可以取得藥品名稱、描述、劑型、價格等詳細資訊。
  • 北美卵巢癌的高發生率是該地區卵巢癌藥物市場的關鍵促進因素，因為它導致對有效治療方法的巨大且持續的需求，從而導致藥物研究和眾多我們推動創新以滿足患者的需求我們的患者群體。
  • 例如，美國癌症協會的 2023 年美國卵巢癌預測預測，大約有 19,710 名女性將新診斷出患有卵巢癌，大約 13,270 名女性將死於卵巢癌。
  • 亞太地區參與臨床試驗的人數不斷增加，這不僅為卵巢癌患者提供了最治療方法，而且還通過吸引製藥公司和研究人員來到該地區來加速藥物開發。卵巢癌治療藥物市場的年複合成長率預計在預測期內最快，為 8.0%。 *。
  • 例如，根據Clinical Trials Arena的數據，從2017年到2022年，亞太地區的臨床試驗增加了約10%，這一增幅令人印象深刻，超過了美國和歐洲等其他主要地區的成長率。該地區這一增速明顯高於同期5.3%的年平均成長率。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 卵巢癌治療藥物市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 卵巢癌治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 卵巢癌治療藥物：按治療層級的估計和趨勢分析

  • 卵巢癌藥物市場：重點
  • 卵巢癌治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • PARP抑制劑
  • 血管新生抑制劑
  • PD-L1抑制劑

第5章 卵巢癌治療：按最終用途分類的估計和趨勢分析

  • 卵巢癌藥物市場：重點
  • 卵巢癌治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章 卵巢癌治療：治療的估計和趨勢分析

  • 卵巢癌藥物市場：重點
  • 卵巢癌治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 化療
  • 放射治療
  • 荷爾蒙治療
  • 標靶治療等

第7章 卵巢癌治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的卵巢癌藥物市場：重點
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • AbbVie Inc.
    • Pfizer, Inc.,
    • AstraZeneca,
    • F. Hoffmann-La Roche AG,
    • Johnson & Johnson Services, Inc.,
    • Boehringer Ingelheim International GmbH,
    • Clovis Oncology,
    • ImmunoGen, Inc.
    • Vivesto AB
Product Code: GVR-2-68038-380-5

Ovarian Cancer Drugs Market Growth & Trends:

The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Ovarian Cancer Drugs Market Report Highlights:

  • Based on treatment, the hospital pharmacy segment held the largest revenue share of 45.37% in 2022. An increasing number of government initiatives and funding for cancer research and treatment are driving drug development and accessibility, ensuring that effective ovarian cancer drugs are available in hospital settings. Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
  • For instance, in 2020, according to the Commonwealth of Australia, the Australian Government allocated USD 16.2 million toward eight research projects dedicated to addressing ovarian cancer. In Australia or globally, ovarian cancer has consistently maintained the lowest survival rate among all female cancers. On average, 43 out of every 100 women diagnosed with ovarian cancer survived five years after their diagnosis.
  • The online pharmacy segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The convenience of online pharmacies in facilitating the ordering and delivery of ovarian cancer drugs directly to patients' homes, particularly those with health limitations, is a significant driver of the online pharmacy segment in the ovarian cancer drugs treatment market. This accessibility eliminates barriers to obtaining essential medications, enhancing patient adherence to treatment regimens and expanding the market reach for these drugs.
  • For instance, AdooQ BioScience provides a convenient platform for customers to order ovarian cancer drugs, specifically Rucaparib. On the webpage, customers can access detailed information about the drug, including its name, description, dosage forms, and pricing.
  • North America dominated the industry with a market share of 43.47% in 2022 due to various factors, such as the high incidence of ovarian cancer in North America is a key driver of the region's ovarian cancer drugs market as it results in a significant and ongoing demand for effective treatments, fostering pharmaceutical research, and innovation to cater to the needs of the substantial patient population.
  • For instance, according to the American Cancer Society's 2023 estimates for ovarian cancer in the United States, approximately 19,710 women are expected to be newly diagnosed, while approximately 13,270 women are projected to lose their lives to ovarian cancer. *
  • Asia Pacific is expected to witness the fastest CAGR of 8.0% over the forecast period due to the increased participation in clinical trials in the region not only provides ovarian cancer patients with access to cutting-edge treatments but also fosters drug development by attracting pharmaceutical companies and researchers, thereby advancing the ovarian cancer drugs market in the region. *
  • For instance, according to the Clinical Trials Arena, from 2017 to 2022, Asia Pacific experienced an impressive increase of approximately 10% in clinical trials, surpassing the growth rate observed in other major regions like the U.S. and Europe. This growth in the region significantly outpaced the overall average of 5.3% per year during the same period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic Class
    • 1.1.2. Treatment
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic class outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Ovarian Cancer Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis

  • 4.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. PARP Inhibitors
    • 4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Angiogenesis inhibitors
    • 4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PD-L1 inhibitors
    • 4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis

  • 5.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Retail pharmacy
    • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Online Pharmacy
    • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis

  • 6.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Chemotherapy
    • 6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Radiation Therapy
    • 6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Hormonal Therapy
    • 6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Targeted Therapy & others
    • 6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. AbbVie Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Pfizer, Inc.,
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. AstraZeneca,
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. F. Hoffmann-La Roche AG,
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Johnson & Johnson Services, Inc.,
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Boehringer Ingelheim International GmbH,
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Clovis Oncology,
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. ImmunoGen, Inc.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Vivesto AB
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 3 North America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 7 U.S. ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S. ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 10 Canada ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 Canada ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 13 Europe ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Europe ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 17 Germany ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 Germany ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 20 UK ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 UK ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 23 France ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 France ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 26 Italy ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Italy ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 29 Spain ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Spain ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 32 Sweden ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Norway ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 35 Norway ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Norway ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Denmark ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 38 Denmark ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 Denmark ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 44 China ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 45 China ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 China ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 48 Japan ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Japan ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 51 India ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 India ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Thailand ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 54 Thailand ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Thailand ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 57 South Korea ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 South Korea ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Latin America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 60 Latin America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Latin America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 63 Brazil ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 64 Brazil ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Brazil ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Mexico ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 67 Mexico ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 68 Mexico ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Argentina ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 70 Argentina ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 Argentina ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Middle East and Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 73 Middle East and Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 74 Middle East and Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 76 South Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 77 South Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 78 South Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 UAE ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 83 UAE ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 84 UAE ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 Kuwait ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 86 Kuwait ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 87 Kuwait ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Ovarian cancer drugs: Market outlook
  • Fig. 9 Ovarian cancer drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Ovarian cancer drugs market driver impact
  • Fig. 15 Ovarian cancer drugs market restraint impact
  • Fig. 16 Ovarian cancer drugs market strategic initiatives analysis
  • Fig. 17 Ovarian cancer drugs market: Therapeutic Class movement analysis
  • Fig. 18 Ovarian cancer drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 19 PARP inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Angiogenesis inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PD-L1 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Ovarian cancer drugs market: Treatment movement analysis
  • Fig. 23 Ovarian cancer drugs market: Treatment outlook and key takeaways
  • Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Ovarian cancer drugs market: End-use movement analysis
  • Fig. 28 Ovarian cancer drugs market: End-use outlook and key takeaways
  • Fig. 29 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Targeted therapy & others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Global ovarian cancer drugs market: Regional movement analysis
  • Fig. 34 Global ovarian cancer drugs market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)